에포에틴 알파

용도

• Adjunctive therapy for anemia associated with endstage renal disease
• Anemia associated with endstage renal disease (PCV <20%)
• Problematic clinical signs and PCV <20%
• Anemia
• Anemia (Rabbits)
• Adjunctive therapy for anemia associated with endstage renal disease
• Adjunctive therapy for anemia associated with endstage renal disease

투여 방법

가능한 부작용

• Autoantibody formation (leading to refractory anemia)
• Systemic hypertension
• Vomiting
• Seizures
• Uveitis
• Iron depletion
• Local reactions at injection sites
• Fever
• Arthralgia
• Mucocutaneous ulcers
• Polycythemia (with chronic overdosage)

주의사항 및 금기

• Uncontrolled hypertension
• Hypersensitivity to epoetin alfa
• Formation of significant autoantibodies with prior treatment
• Equines (not recommended for use)
• Therapy should be started with caution or withheld until corrected in animals with **moderate to severe hypertension** or **iron deficiency**. **Autoantibody Risk:** Up to 30% of patients may develop antibodies significant enough to cause profound anemia and arrestment of erythropoiesis. A bone marrow aspirate showing a myeloid:erythroid ratio >6 predicts significant autoantibody formation and contraindicates further therapy. Discontinue therapy if polycythemia, fever, anorexia, joint pain, cellulitis, or cutaneous/mucosal ulceration occurs.

약물 상호작용

• Androgens: May increase the sensitivity of erythroid progenitors; safety of this combination is not fully determined.
• Desmopressin: Concurrent use with EPO can decrease bleeding times.
• Probenecid: Has been demonstrated to reduce the renal tubular excretion of EPO; clinical significance remains unclear.
• Iron supplements: Synergistic/Required; EPO increases demand for iron to synthesize hemoglobin for new RBCs

자주 묻는 질문